Does national expenditure on research and development influence stroke outcomes?

Area of Science:

• Public Health
• Health Economics
• Epidemiology

Background:

• Gross domestic expenditure on research and development (GERD) is a key macroeconomic indicator for national investment and international comparisons.
• Understanding the relationship between national R&D investment and health outcomes like stroke is crucial for global health policy.

Purpose of the Study:

• To investigate the association between national research and development expenditures and stroke incidence and mortality.
• To explore if variations in GERD influence global stroke burden.

Main Methods:

• Comparative analysis of stroke metrics (mortality, incidence) with GERD indicators (absolute per-capita adjusted for PPP, relative to GDP).
• Utilized data from international organizations (UNESCO, WHO, World Bank) and population-based studies.
• Employed correlation analysis and multivariable linear regression modeling.

Main Results:

• A significant inverse association was found between age-standardized stroke mortality rates and both absolute (aGERD) and relative (rGERD) research and development expenditures in 2002 and 2008 (p < 0.001).
• Lower aGERD and rGERD were independently linked to higher stroke mortality (p < 0.05).
• Countries with lower R&D spending exhibited higher prevalence of hypertension, diabetes, and obesity. Population-based studies confirmed inverse associations between GERD and stroke risk/fatality.

Conclusions:

• Higher stroke mortality rates are observed in countries with lower expenditures on research and development.
• Findings suggest that increased R&D investment could be a potential strategy for improving global stroke outcomes.
• While causality is not proven, the study highlights R&D investment as an area for intervention to mitigate stroke burden.